JAMA's policy on industry sponsored studies

Comment

Phil B Fontanarosa et al. BMJ. 2006.

. 2006 Jan 21;332(7534):177.

doi: 10.1136/bmj.332.7534.177.

No abstract available

Comment in

JAMA's policy does not go far enough.
Senn SJ. Senn SJ. BMJ. 2006 Feb 4;332(7536):305. doi: 10.1136/bmj.332.7536.305-a. BMJ. 2006. PMID: 16455745 Free PMC article. No abstract available.
More on JAMA's policy on industry sponsored studies.
Rothman KJ, Evans S. Rothman KJ, et al. BMJ. 2006 Feb 25;332(7539):489. doi: 10.1136/bmj.332.7539.489-a. BMJ. 2006. PMID: 16497774 Free PMC article. No abstract available.

Extra scrutiny for industry funded trials.
Rothman KJ, Evans S. Rothman KJ, et al. BMJ. 2005 Dec 10;331(7529):1350-1. doi: 10.1136/bmj.331.7529.1350. BMJ. 2005. PMID: 16339222 Free PMC article. No abstract available.

1. Rothman KJ, Evans S. Extra scrutiny for industry funded trials. BMJ 2005;331: 1350-1. (10 December.) - PMC - PubMed
1. Fontanarosa PB, Flanagin A, DeAngelis CD. Reporting conflicts of interest, financial aspects of research, and role of sponsors in funded titles. JAMA 2005;294: 110-1. - PubMed
1. Curfman GD, Morrisey S, Drazen JM. Expression of concern: Bombardier et al. “Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis,” N Engl J Med 2000;343: 1520-8. N Engl J Med 2005;2813-4. - PubMed
1. Hrachovec JB, Wright JM. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. JAMA 2001;286: 2398. - PubMed
1. Gibson L. GlaxoSmithKline to publish clinical trials after US lawsuit. BMJ 2004;328: 1513. - PMC - PubMed